autopsy. Magnetic resonance imaging allows excellent anatomical definition of this area and makes it possible to identify tectal lesions of all histological types. Typically ellipsoid, these lesions are characteristically well defined, hypo-or isointense on T 1 -weighted MR images, hyperintense on T 2 -weighted images, and rarely show enhancement with the addition of contrast agents. 1 Less frequently, tectal lesions can be identified on CT scans, if they are unusually large or calcified. Although the advent of MR imaging has allowed us to identify and monitor tectal plate lesions, on the whole it still has not allowed us to distinguish easily low-grade tumors from hamartomas in this region. Potentially, MR imaging can help differentiate these lesions; indeed, few demonstrate clear tumor characteristics (such as large volume, contrast enhancement, and cystic degeneration-all features clearly different from native tissue and not indicative of hamartoma). The anatomical location of these tumors and the consequent hydrocephalus suggest that they present as small lesions, and it is at this point in their natural history that small tumors can mimic tectal plate hamartomas.
A review of the literature indicates that, although 80% of tectal plate lesions are benign gliomas, a small percentage are malignant lesions. 8, 11, 15 There is a case selection bias, however, because in at least half of the cases the pathological entity is unknown, and children harboring tumors with imaging and clinically benign features are treated for hydrocephalus only. Although hamartomas generally do not progress enough to require biopsy sampling or resection, histological confirmation of these lesions in this region has been obtained from autopsy series. 9, 10 One school of thought holds that the differentiation of these lesions is more academic than practical and that, regardless of histological features, these lesions typically behave in a benign and indolent fashion, leading clinicians to refer to them all as "benign intrinsic tectal tumor(s)." 12 Because long-term reviews of MR imaging surveillance are now available, however, it is apparent that although their growth pattern is slow and their histological features are low grade, a proportion of the tumors in this region will continue to grow (18 to 31% of tumors, as reported in the literature 15, 16, 21 ) and will eventually require treatment. Despite a long latency period (7.8 years from shunt insertion or 11.5 years from the onset of initial symptoms 16 ), the clinical course of growing tumors usually involves the brainstem and causes neurological deficits. Our clinical impetus is to determine whether these lesions can be treated earlier so that outcomes can be improved.
Clinical Material and Methods
In an effort to refine treatment of children with tectal lesions, we reviewed our hospital's records from 1984 through 2003, during which MR imaging was used, to define clinical or neuroimaging features identified at presentation that predict the need for future treatment. With the rationale of limiting overinvestigation, we also reviewed the data in terms of duration and frequency of neuroimaging follow up.
We retrospectively reviewed all pediatric cases involving tectal plate lesions confirmed on MR imaging and treated at Hôpital Necker-Enfants Malades over the past 20 years. Each case was reviewed for the initial clinical presentation and the mean delay between the patient's first symptoms and presentation to our hospital. Symptoms at onset were noted, such as signs of raised intracranial pressure, gait disturbance, vertigo, ataxia, strabismus, Parinaud syndrome, and any concurrent pathological condition.
The radiological features of CT scans, the presence or absence of hydrocephalus, and the presence of calcification or visible lesions were noted. Magnetic resonance images (T 1 -weighted, T 2 -weighted, and contrast-enhanced) were obtained at presentation, and the children were monitored with follow-up MR imaging. For each MR imaging study, we measured the lesion and calculated the volume using a formula based on elliptical volume (4[a ϫ b ϫ c]/3). The lesion volume calculations were performed using the latest available MR images for conservatively managed cases and after each operation for surgically treated cases.
Note was also made of operative findings, histopathological features, and any adjuvant therapy (such as chemotherapy and/or radiotherapy). The duration of follow up and the patient's clinical state were recorded. Statistical analysis was performed using commercially available software (SPSS version 11.5; SPSS, Inc., Chicago, IL) to perform the Mann-Whitney nonparametric test and the Student t-test.
Results

Population Profile
Forty children were eligible for inclusion in the study, 28 girls and 12 boys (male/female ratio 2.3:1). The median age at onset was 9.4 years (range 0-17.6). The mean delay between the patient's first symptom and the time of presentation at our hospital was 8.5 months. The series included two children with NF1. The children were followed up for a mean of 4.36 years. The clinical signs at presentation are noted in Table 1 .
Symptoms relating to increased intracranial pressure constituted the presentation in the majority of cases. Parinaud syndrome was rarer than expected, and only one child had internuclear ophthalmoplegia.
Management of Hydrocephalus
For the majority of the patients (37 of 40) the first intervention was surgery for hydrocephalus. As noted previously, these patients presented at a mean delay of 8.5 months from the first clinical symptom. In keeping with the preference of our service for ETV, 27 of these children underwent this procedure and the remaining 10 were treated for varying reasons with shunt placement. Nine of the 27 patients who underwent ETV required another surgical procedure at a mean of 6 months after the initial surgery. Five of these additional procedures were undertaken to correct the original surgical technique (the stoma was too small) and four were undertaken to deal with a stomal obstruction present after tumor surgery in the prone position (presumably caused by pooling of blood products). All nine repeated operations were successful, and no future revisions were required. Eight of the 10 children with shunts required a revision in the first 3 years after the device had been inserted.
During the follow-up period (Յ 21 years), 26 of 40 patients remained in stable condition, as determined clinically and according to imaging studies, and continued to participate in MR imaging and clinical surveillance. Fourteen patients demonstrated tumor progression necessitating surgical intervention.
Imaging Findings
All patients in the series had undergone CT scanning without the presence of a tectal lesion being identified. A retrospective examination of the CT scans demonstrated tectal hyperdensity in two cases, hypodensity in five cases, and a degree of contrast enhancement in the region of the tectal Table 2 details the neuroimaging features that were found. The typical pattern was hypo-or isointensity on T 1 -weighted images and hyperintensity on T 2 -weighted images; contrast enhancement was seen rarely (only two of five histologically confirmed pilocytic astrocytomas exhibited contrast enhancement). Frequently, these lesions appear on T 1 -weighted images to be a diffuse enlargement of the tectal plate, with T 2 -weighted images providing delineation and localization of the lesions (typically in relation to the colliculi of the quadrigeminal plate). The tumors of two patients in this series demonstrated diffuse tectal plate enlargement only, which was isointense on both T 1 -and T 2 -weighted images.
Using MR images obtained at presentation, postoperatively (if applicable), and most recently, we calculated the volume of each lesion (Fig. 1) . The mean lesion volume at presentation was 5.4 cm 3 and the lesion volume ranged from diffuse tectal enlargement to a maximum of 32 cm 3 . An analysis of lesion volume distribution at presentation ( Fig. 2) produced breakpoints enabling the series to be divided into three groups at 1.5 and 3.9 cm 3 . This grouping according to lesion size was then used for statistical analysis of management and outcomes.
Surgically Managed Cases
Fourteen patients experienced tumor enlargement or imaging changes that required surgery (Table 3 ). In this group the mean latency between the treatment of hydrocephalus and tumor surgery was 20 months (range 10 days-6.5 years), and the mean volume at presentation was 11.6 cm 3 . Three children underwent continued surveillance of more than 20 months, despite evidence of lesion enlargement before eventual surgery. The first patient (Case 20), had a tumor with a lesion volume of 2.55 cm 3 at referral that subtly increased in size over 75.13 months and was found through histological analysis to be dysplasia. The other two children (Cases 37 and 40) had tumors with lesion volumes of 16.4 and 32 cm 3 at presentation; these children were treated at our hospital for hydrocephalus and then, because they lived far from Paris, were eventually followed up by physicians at their home hospitals. The tumors in both children were subsequently identified as low-grade astrocytomas, and the patients were referred back to our hospital when clinical signs eventually developed, 35.87 and 78.9 months, respectively, after the initial presentation.
All the lesions were approached through an interhemispheric transtentorial route. To reduce morbidity rates, surgery for large tumors was performed in several stages when necessary. The macroscopic appearance of these large tumors was almost identical to that of normal brain tissue. There were no perioperative deaths. Transient postoperative Parinaud syndrome was observed in almost all cases in the series. Permanent morbidity occurred in six cases (43%): two children with Parinaud syndrome, one child with nystagmus, one with an ophthalmoplegia, one with epilepsy, and one with a hemisensory deficit ( Table 3 ). All but one (Case 38) of these children had these signs at presentation. The only death in this group (and in the series) was that of the child with the high-grade glioma who died of disease progression.
The mean follow-up period for this operative cases subgroup is 3.8 years. One patient (Case 31) was considered "lost" because he returned to Africa, where he was followed up. Eleven of the 14 tumors were histologically determined to be low-grade glial tumors (including five pilocytic astrocytomas); there was one high-grade glioma and one case of dysplasia. In Case 1, in which the child presented with diffuse enlargement, histological examination revealed no features indicative of a tumor. Postoperative MR imaging re- vealed residual lesions in 10 cases (71%); however, on continued surveillance (mean 25.4 months, range 9-54 months) only four of these lesions demonstrated continued enlargement, and one first appeared when contrast enhancement was used. All five children underwent surgery a second time. Complete resection was accomplished in two patients. The remaining three patients had small residual lesions, although one child (Case 33) remained stable after the second surgery. Regarding the two cases in which ongoing progression was demonstrated, one patient (Case 38) was treated with radiotherapy and a third surgery through which complete excision was accomplished, and the second (Case 40) has continued to participate in neuroimaging follow up and remains clinically well. The sole high-grade glioma (Case 34) exhibited early invasion and contrast enhancement. Despite treatment with radiotherapy, the tumor continued to progress and the patient eventually died of his disease.
Conservatively Managed Cases
For the children who did not undergo surgery, the mean follow-up period was 7 years (compared with 3.8 years for the operative group and 4.36 years for the entire series). The mean tumor volume at presentation was 2.33 cm 3 . At presentation and prior to the management of hydrocephalus, 17 (65%) of these children had a neurological deficit. Seven children (27%) were left with a permanent neurological deficit, six of whom had exhibited the deficit as the first clinical sign.
Correlation Analysis
There was no statistical relationship between the tumor volume at presentation and the delay between the first symptom and presentation to our hospital. Additionally, there was no significant difference in this delay between the operative and nonoperative cases (9.7 and 8.5 months, respectively).
There was no correlation between the lesion volume and the presence of contrast enhancement in our series; however, there was a statistically significant correlation between the lesion volume at referral and the subsequent risk of progression observed on neuroimages (as seen through enlargement, contrast enhancement, or invasion; p = 0.03, with a mean volume of 3.8 cm 3 for stable lesions). The surgical management was significantly influenced by the lesion volume at referral (p = 0.002). The mean lesion volume for patients who underwent surgery was 11.6 cm 3 as compared with 2.3 cm 3 for those who did not. Figure 3 shows the tumor volumes for both groups at referral, before surgery (if applicable), and at last follow up.
After analysis of the series distribution by lesion volume at referral, the population falls into three groups, as illustrated in Fig. 4 . Figure 5 provides a closer look at the heterogeneous group having a tumor volume less than 10 cm 3 and shows that this group falls into two subgroups. The . There were three cases in which lesions with volumes less than 4 cm 3 were surgically treated. In the first, the child had NF1 and in the other two cases the lesions demonstrated increasing size or contrast enhancement. In this subgroup of lesions with volumes less than 10 cm 3 , all were low-grade astrocytomas identified histologically.
In a comparison of growth patterns between the two groups, we found a rise in volume to 4 cm 3 in the conservatively managed group over a mean period of 7 years; however, in the surgically managed group a mean volume rise to 22 cm 3 was seen over a mean period of 2 years. There was no statistically significant difference between the groups in terms of clinical outcome and permanent morbidity.
Population Subgroups
To analyze the patient population for future tumor progression and the need for additional treatment, the series can be divided into three groups by tumor volume thresholds (Ͻ 4, 4-10, and Ͼ 10 cm 3 ). Table 4 depicts the series broken into these three subgroups and details the treatment course for each case. Despite the fact that all patients in the subgroup who had large lesions eventually proceeded to surgery, it is interesting that there was marked heterogeneity between surgeons regarding the time they allowed to elapse from presentation to surgery.
Discussion
In the era before MR imaging, children harboring tectal plate lesions were often provided with shunts for late-onset aqueductal stenosis, and few came to the attention of physicians because of obvious tumor progression. The so-called benign and indolent nature of these lesions was undermined by the sometimes insidious onset of symptoms. The advent of MR imaging as a diagnostic tool and improved anatomical definition enabled neurosurgeons to debulk and resect these lesions. Authors of reported series 4, 7, 11, 18 show that these procedures can be performed with limited morbidity and with good long-term outcomes. Conversely, results of many studies confirmed the historical precedent of positive outcomes being achieved through conservative management. 5, 12, 20 The literature remains divided between resection, biopsy sampling procedures and adjuvant therapy, and conservative management-all of which achieve similar outcomes. This range of management strategies derives from the diversity of the lesions, which include both tumors and hamartomas. We theorize that by identifying likely tumors and hamartomas at presentation we can provide a more structured management approach for children harboring them, thus avoiding both overtreatment of the hamartomas and undertreatment of the tumors. By earlier identification and treatment of lesions requiring surgery, we should be able to limit the clinical progression to neurological deficit and to intervene at a time when the surgery is technically easier and morbidity is minimized.
In keeping with the literature, the majority of surgically treated lesions in our series were histologically benign. many tectal plate lesions being managed without biopsy specimens being obtained. The success of ETVs for management of the associated hydrocephalus (as demonstrated in this series and others 3, 16, 21 ) and the technological improvements in endoscopes introduces the ability to undertake concurrent biopsy sampling procedures. Although it was not undertaken in this series, the technique has been reported with success. [13] [14] [15] As yet, however, no reported data exist on the utility of obtaining small biopsy specimens in this mixed population of children harboring hamartomas and low-grade tumors.
The most frequent adjective applied to these lesions in the literature is "indolent," 2, 6, 12, 19 and certainly when we review patient age and volume distribution of the tumors at presentation in relation to the time to progression, tectal plate lesions are found to be relatively slow growing. This study confirms the indolent nature of these lesions and suggests a bimodal pattern of ones that remain stable and ones that are slowly progressive. It is known that a proportion of these tumors will progress, and patients harboring them often present with neurological deficits. 16, 17 The management of progression using radiotherapy and/or surgery aims to limit tumor growth, but such treatment is not always associated with reversal of such deficits to the brainstem. With an increased ability to identify a subgroup of lesions likely to progress, we hypothesize that earlier intervention prior to the development of neurological deficits will result in improved outcomes for these children.
The intuitive concept that tumor size at presentation is predictive of the necessity for intervention has previously been examined by Poussaint, et al. 17 In their retrospective review of 32 cases of children harboring tectal tumors, maximal tumor diameter and contrast enhancement were used to calculate the likelihood of further treatment being required (typically radiotherapy in their series). In our series, contrast enhancement was rare (and therefore was not statistically significant). In two cases, however, the development of a new area of contrast enhancement prompted surgery, despite the unaltered lesion volume. Tumor volume, on the other hand, was strongly statistically significant as a predictor of the need for surgery. By using a volume assessment based on the typical ellipsoid shape of these lesions and combining it with clinical features, the population in this series falls into the following three distinct subgroups.
Small Lesions (2-4 cm 3
). These tumors typically do not show enhancement with the addition of contrast agents, and they remain stable over time (Fig. 6 left) . This group likely represents the so-called "hamartomas" reported in the literature. In this series, this subgroup comprised slightly more than one half (22 of 40 patients) of the entire population of children having tectal plate lesions. Despite the relatively stable nature of these lesions, the results of this study demonstrate that children harboring them must remain under continued surveillance, for after a mean period of 3.5 years (range 1-75 months), three children (13.6%) required surgery. Of the three lesions progressing to a size that warranted surgery, only one low-grade tumor was identified (one was a dysplasia and the other was not identified). The low-grade tumor was also somewhat atypical, because surgery was indicated not for an increase in size but for the development of contrast enhancement.
Medium-Sized Lesions (4-10 cm 3
). Of the 11 patients within this volume range, seven remain in stable condition, as determined clinically and according to neuroimages at a mean follow-up period of 7 years (Fig. 6 center) . The tumors in the four other patients developed imaging altera- tions and required surgical intervention within the 1st year of surveillance (mean 7 months). Histological examinations revealed all these lesions to be low-grade astrocytomas.
Large Lesions (Ͼ 10 cm 3
). In seven patients in our series tumor volume was greater than 10 cm 3 (mean 20 cm 3 ; Fig.  6 right) . This group includes the patient with a high-grade astrocytoma who died despite radiotherapy. In this historical series, gross-total resection was rarely achieved at first surgery (nine of 14 first operations). Patients with residual tumor underwent a second surgery if signs of progression or contrast enhancement were identified.
Although it is likely that the subgroup of small lesions represents the group of hamartomas and the group of large lesions the tumors, it remains difficult to predict the behavior of the medium-sized lesions. The majority of them have a maximal diameter within the 15-to 20-mm range and thus would fall under the traditional term "benign tectal plate glioma" in the literature. 12, 16, 17, 19 More than one third of these patients had tumors that developed neuroimaging features suggestive of progression (enlargement, contrast enhancement, or cystic change) and thus underwent surgery.
Lesion volume at presentation was the only predictor of future tumor enlargement (and therefore of surgical management). Clinical signs at presentation related mainly to the associated hydrocephalus; however, the development of neurological signs despite successfully treated hydrocephalus usually heralded tumor progression. Data from our series are consistent with previous findings that contrast enhancement, invasion of surrounding structures, and neurological deficit are poor prognostic factors and that further treatment is warranted when they are present. 12, 16 The association with NF1 has been described previously, 16 ,17 yet its prognostic significance remains undefined, making the unexpected progression of a small lesion in a patient with NF1 interesting.
This series represents a practice in which the philosophy for intervention has been surgical in an attempt to avoid or delay radiotherapy. Although advances in radiotherapy limit these concerns, fundamentally we all aim to limit radiotherapy to the developing brain if a relatively safe and effective surgical option exists. Additionally, young patients with low-grade lesions face the specter of postirradiation anaplasia. In the surgical subgroup of this series, only one patient experienced a neurological deficit that had not been present preoperatively. In 10 of 14 cases, residual tumor was evident on the postoperative MR images, although only four of these patients experienced continued tumor enlargement. Although small in number, the patients who required more than one operation or adjuvant therapy all had large-volume lesions. We speculate that early identification of tumors behaving aggressively may reduce the requirement for multiple surgeries or adjuvant therapy.
It is recognized that tectal plate lesions mandate longterm clinical and neuroimaging surveillance; however, the loss of many of these children to adult populations has limited the number of long-term series reports. Pollack, et al., 16 recommend clinical and imaging examination every 6 months for a year and yearly for 4 years followed by annual clinical examinations and MR imaging every 2 or 3 years for stable patients. Despite our evidence that tumors measuring less than 4 cm 3 at presentation are less likely to progress, children harboring them still require long-term clinical and neuroimaging surveillance. We postulate that patients whose lesions measure 4 to 10 cm 3 require frequent initial imaging based on the significant number of such cases in which tumor progression is seen within the 1st year. Finally, for patients whose lesions are larger than 10 cm 3 , we recommend a consideration of earlier treatment to optimize outcome.
Conclusions
This review of tectal plate lesions treated since MR imaging became available at our hospital confirms that children harboring them usually present in a delayed fashion with symptoms and signs referable to hydrocephalus. In keeping with cases described in the literature, the associated hydrocephalus was most successfully treated with ETV. Although at least one half of these lesions demonstrate a benign and indolent clinical nature, there was a subgroup of progressive lesions that required treatment. The only statistically significant predictor of future enlargement was We conclude from our analysis of this series that all children presenting with late-onset aqueductal stenosis should undergo contrast-enhanced MR imaging and careful clinical examination. The associated hydrocephalus is best managed with ETV, both initially and (in our experience) at recurrence. We now calculate lesion volumes both at presentation and on subsequent imaging so that these children can receive optimal treatment. Children harboring small lesions (which are likely hamartomas) remain under long-term clinical and neuroimaging surveillance into adulthood. Medium-sized lesions (potentially either tumors or hamartomas) also warrant long-term follow up with increased frequency in the first few years. We now have a lower threshold for surgical intervention in cases of larger lesions. All of the large lesions in our series eventually required surgery, and in some instances repeated or adjuvant surgery was necessary. We hope that by intervening earlier we can improve the outcome for this subgroup of children.
